Latest
Long-Term Efficacy of Zanubrutinib Confirmed for Mantle Cell Lymphoma
Parsaclisib May Be Safe, Effective in Autoimmune Hemolytic Anemia
Response to Axicabtagene Ciloleucel Superior to Standard Care in R/R Large B-Cell Lymphoma
Guidelines for CML Not Followed in the Real World
Half of Hospitals Have Implemented No Price Transparency
Pembrolizumab May Improve Responses to Consolidation in Pediatric Classic Hodgkin Lymphoma
Allo-HSCT: Unrelated, Haploidentical Donations May Yield Similar Outcomes
Predicting Disease Progression in Patients With MALT Lymphoma
Survivors of Medulloblastoma Have Greater Risk of Stroke, Severe Hearing Loss
Venetoclax Plus Obinutuzumab May Improve PFS, Not OS in Chronic Lymphocytic Leukemia
Long-Term Prophylaxis Cost-Effective for Von Willebrand Disease
Triplet Maintenance After HSCT Improves PFS vs Lenalidomide Alone in Multiple Myeloma
Featured Content
FDA Aims To Improve Medical Device Security
The agency has issued proposed draft recommendations to guide incorporation of cybersecurity protections into medical devices at the time of manufacture.
Radiomics: An Emerging Frontier in Cancer Diagnostics, Treatment Planning
This overview of radiomics explains its potential for improving diagnosis, predictions of tumor response and recurrence, and patient prognosis.
Risk of Cancer-Specific Death May Remain Elevated for 30 Years
Patients with certain cancers have an increased risk of cancer-specific mortality that persists for 30 to 35 years after diagnosis.
Addressing Psychological Distress After VTE
Researchers are seeking to address the psychological impact of patients who have survived VTE.
- Loading...
Loading...
Loading... 
Loading...